104 ASTRAZENECA ANNUAL REPORT AND FORM 20-F INFORMATION 2006 NOTES TO THE FINANCIAL STATEMENTS 1 OPERATING PROFIT 2006 2005 2004 $m $m$m Group operating profit 8,216 6,502 4,547 Charges included above for depreciation 950 965 921 for amortisation 325 272 306 for impairment 70 90 41 Gross profit 20,916 18,594 16,233 Impairment charges in 2006 relate to the write-down of assets in respect of Toprol-XL, NXY-059 and a collaboration agreement.
Impairment charges in 2005 relate to the write-down of assets associated with capacity reviews at manufacturing sites, primarily in the UK and France.
Cost of sales in 2004 includes charges against inventories and prepayments in respect of Exanta and Iressa totalling $195m.
In addition, the charge for impairment in 2004 arose from writing off property, plant and equipment and goodwill associated with Exanta and Iressa.
2006 2005 2004 $m $m $m Other operating income and expense Royalties 327 165 95 Other income and expense 197 28 131 524 193 226 Other income and expense includes gains and losses arising from disposals under ongoing product and investment rationalisation programmes.
2 PROFIT ON SALE OF INTEREST IN JOINT VENTURE 2006 2005 2004 $m $m $m Profit on sale of interest in joint venture 219 Net taxation credit 9 Total profit on sale of interest in joint venture after taxation 228 The profit on sale of interest in joint venture in 2004 relates to the disposal of the Groups interest in the Ordinary Share capital of Advanta BV.
There is a tax credit of $9m arising on costs associated with the disposal.
